CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
61.96
-2.72 (-4.21%)
Nov 2, 2026, 4:00 PM EST - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $91.08. The average 1-year stock price forecast is 47.00% higher than the current stock price, while the lowest is $79 (+27.50%) and the highest is $108 (+74.31%).
Price Target: $91.08 (+47.00%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Initiates $90 | Buy | Initiates | $90 | +45.26% | Oct 22, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 10, 2026 |
| UBS | UBS | Buy Reiterates $90 | Buy | Reiterates | $90 | +45.26% | Aug 20, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $93 | Buy | Reiterates | $93 | +50.10% | Aug 17, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $108 | Buy | Maintains | $108 | +74.31% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
4.45M
from 4.04M
Increased by 10.26%
Revenue Next Year
83.51M
from 4.45M
Increased by 1,774.76%
EPS This Year
-3.23
from -2.08
EPS Next Year
-3.02
from -3.23
EPS and Forward PE are based on non-GAAP adjusted numbers.